I always feel like the start of a new year arrives with a certain amount of pressure. We make resolutions, talk about reinvention, and make quiet promises to ourselves that we’ll do better. As someone living with neuromyelitis optica spectrum disorder (NMOSD), that pressure can feel especially heavy. Chronic…
Newer, more potent therapies offer greater benefit than standard immunosuppressants in reducing relapse rates for people who develop neuromyelitis optica spectrum disorder (NMOSD) after the age of 50, according to a large, single-center study in China. While people with late-onset NMOSD experienced more severe symptoms at onset and during…
People with neuromyelitis optica spectrum disorder (NMOSD) have significantly higher levels of chitotriosidase-1 (CHIT1), a protein involved in immune and inflammatory responses, in their cerebrospinal fluid (CSF), the liquid surrounding the brain and spinal cord, a study shows. CSF CHIT1 levels were also significantly associated with NMOSD activity and severity.
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
